Gland Pharma Limited Cash Flow Conversion Efficiency
Gland Pharma Limited cash flow conversion efficiency. Based on the latest financial reports, Gland Pharma Limited (GLAND) has a cash flow conversion efficiency ratio of 0.062x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs5.93 Billion ≈ $64.16 Million USD) by net assets (Rs95.63 Billion ≈ $1.03 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Gland Pharma Limited (2017–2026)
Cash flow conversion efficiency of Gland Pharma Limited from 2017 to 2026. This chart illustrates how Gland Pharma Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Gland Pharma Limited stock quote for real-time trading data and today's change.
Gland Pharma Limited Cash Flow Conversion Ratio Explained
Gland Pharma Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Gland Pharma Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gland Pharma Limited ranked by their cash flow conversion efficiency. Also see how much is Gland Pharma Limited worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OceanaGold Corporation
TO:OGC
|
0.119x |
|
SBI Cards and Payment Services Limited
NSE:SBICARD
|
0.007x |
|
MaxLinear Inc
NASDAQ:MXL
|
-0.020x |
|
JUSUNG ENGINEERING Co. Ltd
KQ:036930
|
-0.027x |
|
Koninklijke Vopak NV
AS:VPK
|
0.107x |
|
Perseus Mining Ltd
AU:PRU
|
0.180x |
|
Terawulf Inc
NASDAQ:WULF
|
-0.927x |
|
NEXANS ADR EO 1
F:NXS0
|
N/A |
Annual Cash Flow Conversion Efficiency for Gland Pharma Limited (2017–2026)
The table below shows the annual cash flow conversion efficiency of Gland Pharma Limited from 2017 to 2026. Review how much free cash does Gland Pharma Limited generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | Rs103.58 Billion ≈ $1.12 Billion |
Rs12.31 Billion ≈ $133.16 Million |
0.119x | +18.92% |
| 2025-03-31 | Rs91.51 Billion ≈ $989.62 Million |
Rs9.15 Billion ≈ $98.92 Million |
0.100x | -12.51% |
| 2024-03-31 | Rs87.24 Billion ≈ $943.45 Million |
Rs9.97 Billion ≈ $107.80 Million |
0.114x | +149.85% |
| 2023-03-31 | Rs79.59 Billion ≈ $860.71 Million |
Rs3.64 Billion ≈ $39.36 Million |
0.046x | -58.61% |
| 2022-03-31 | Rs71.58 Billion ≈ $774.07 Million |
Rs7.91 Billion ≈ $85.52 Million |
0.110x | +7.81% |
| 2021-03-31 | Rs59.03 Billion ≈ $638.41 Million |
Rs6.05 Billion ≈ $65.42 Million |
0.102x | -46.69% |
| 2020-03-31 | Rs36.46 Billion ≈ $394.33 Million |
Rs7.01 Billion ≈ $75.80 Million |
0.192x | +196.98% |
| 2019-03-31 | Rs28.62 Billion ≈ $309.51 Million |
Rs1.85 Billion ≈ $20.03 Million |
0.065x | -22.80% |
| 2018-03-31 | Rs24.10 Billion ≈ $260.67 Million |
Rs2.02 Billion ≈ $21.86 Million |
0.084x | -63.22% |
| 2017-03-31 | Rs20.90 Billion ≈ $226.01 Million |
Rs4.76 Billion ≈ $51.53 Million |
0.228x | -- |
About Gland Pharma Limited
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The … Read more